# Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

> **NCT04178798** · PHASE3 · COMPLETED · sponsor: **PETHEMA Foundation** · enrollment: 22 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia- Binet Staging System

## Interventions

- **DRUG:** Acalabrutinib 100 MG Oral Capsule

## Key facts

- **NCT ID:** NCT04178798
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-09
- **Primary completion:** 2024-12-03
- **Final completion:** 2024-12-03
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04178798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04178798, "Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04178798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*